Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

Reiteration

Reiteration

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Wedbush Reiterates Outperform on Chipotle Mexican Grill, Maintains $2080 Price Target

By Benzinga Newsdesk
March 17, 8:25 AM
Wedbush analyst Nick Setyan reiterates Chipotle Mexican Grill (NYSE:CMG) with a Outperform and maintains $2080 price target.

CMG

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target

By Benzinga Newsdesk
March 17, 8:14 AM
Wedbush analyst Robert Driscoll reiterates Geron (NASDAQ:GERN) with a Outperform and maintains $6 price target.

GERN

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Oppenheimer Reiterates Outperform on Microvast Holdings, Maintains $8 Price Target

By Benzinga Newsdesk
March 17, 8:08 AM
Oppenheimer analyst Colin Rusch reiterates Microvast Holdings (NASDAQ:MVST) with a Outperform and maintains $8 price target.

MVST

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Oppenheimer Reiterates Outperform on Five Below, Maintains $235 Price Target

By Benzinga Newsdesk
March 17, 8:06 AM
Oppenheimer analyst Brian Nagel reiterates Five Below (NASDAQ:FIVE) with a Outperform and maintains $235 price target.

FIVE

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

Needham Reiterates Buy on TerrAscend, Announces $1.75 Price Target

By Benzinga Newsdesk
March 17, 6:44 AM
Needham analyst Matt McGinley reiterates TerrAscend (OTC:TRSSF) with a Buy and announces $1.75 price target.

TRSSF

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on AC Immune, Maintains $16 Price Target

By Benzinga Newsdesk
March 17, 6:42 AM
HC Wainwright & Co. analyst Andrew Fein reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $16 price target.

ACIU

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $22 Price Target

By Benzinga Newsdesk
March 17, 6:38 AM
HC Wainwright & Co. analyst Robert Burns reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $22 price target.

IKNA

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Armata Pharmaceuticals, Maintains $7 Price Target

By Benzinga Newsdesk
March 17, 6:34 AM
HC Wainwright & Co. analyst Joseph Pantginis reiterates Armata Pharmaceuticals (AMEX:ARMP) with a Buy and maintains $7 price target.

ARMP

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $14 Price Target

By Benzinga Newsdesk
March 17, 6:31 AM
HC Wainwright & Co. analyst Ed Arce reiterates Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy and maintains $14 price target.

ACXP

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target
  • Reiteration

HC Wainwright & Co. Reiterates Buy on TFF Pharmaceuticals, Maintains $22 Price Target

By Benzinga Newsdesk
March 17, 6:30 AM
HC Wainwright & Co. analyst Vernon Bernardino reiterates TFF Pharmaceuticals (NASDAQ:TFFP) with a Buy and maintains $22 price target.

TFFP

Posts pagination

Previous 1 … 239 240 241 … 399 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service